CIHR CLINICAL TRIALS PROJECTS – SECOND ROUND (2024)
On August 13, the Honourable Mark Holland, Minister of Health, announced that the Government of Canada is investing more than $43 million to support 14 new clinical trials focused on preparing Canada to respond to future health emergencies and advancing the country’s life sciences sector.
Researchers at the RI-MUHC will lead four of the fourteen newly funded clinical trials.
- Patrick Lawler, MD: CLEAR-HORIZONS Post-Sepsis Platform Trial: Statin Pilot RCT
- Dick Menzies, MD: Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
- Ruth Sapir-Pichhadze, MD, PhD: Efficacy and safety of COVID-19 vaccine Co-administration and Interval in Immunocompromised hosts (CO2I2 Trial)
- Makeda Semret: Biomarker-signature Supported Antibiotic Treatment Decisions in ICU (BAST-ICU)
The full list of funded clinical trials can be found here: CIHR Clinical Trials Projects. These trials are being supported by the Canadian Institutes of Health Research (CIHR) Clinical Trials Fund, an important part of Canada’s Biomanufacturing and Life Sciences Strategy, and Canada’s Strategy for Patient-Oriented Research.
—Published August 15, 2024